13 September, 2022
White paper summary:
Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains a significant cause of in-hospital mortality in healthcare centers across the world [1-3]. Several public health campaigns endorsed by large national organizations are focused on improving the management of patients with sepsis and septic shock (defined as those with circulatory and cellular and/or metabolic dysfunction) [1].
The Society of Critical Care Medicine and the European Society of Intensive Care Medicine have worked to develop the “Surviving Sepsis Campaign” which aims to reduce sepsis-related mortality by educating healthcare professionals and improving diagnosis and treatment, as outlined in a comprehensive set of guidelines available for clinicians [4].
Click below to access the white paper sponsored by Xellia Pharmaceuticals USA LLC, Surviving Sepsis: Importance of Timely Antibiotic Administration, authored by Twisha S. Patel (Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and the University of Michigan College of Pharmacy, Ann Arbor, Michigan) and Keith S. Kaye (Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI).